Globotriaosylsphingosine improves risk stratification of kidney progression in Fabry disease patients-Reference-Cited by-同舟云学术

Globotriaosylsphingosine improves risk stratification of kidney progression in Fabry disease patients

Published:2024-03 Issue: Volume:556 Page:117851
ISSN:0009-8981
Container-title:Clinica Chimica Acta
language:en
Short-container-title:Clinica Chimica Acta

Author:

Ouyang Yan,Zhang Wei,Zhao Zhanzheng,Wang Chaohui,Ren Hong,Xie Jingyuan,Li Xiao,Shen Pingyan,Shi Hao,Xu Jing,Xu Yaowen,Wang Weiming,Yang Li,Yu Xialian,Chen Weihong,Zhao YaWen,Wang Zheng,Wu YiFan,Chen Nan,Pan XiaoXia

Funder

National Natural Science Foundation of China

Shanghai Rising-Star Program

Publisher

Elsevier BV

Reference37 articles.

1. Angiokeratoma corporis diffusum–fabry disease: historical review from the original description to the introduction of enzyme replacement therapy;Fabry;Acta Paediatr Suppl.,2002

2. Genotype: a crucial but not unique factor affecting the clinical phenotypes in fabry disease;Pan;PLoS One.,2016

3. Screening, diagnosis, and management of patients with fabry disease: conclusions from a “kidney disease: improving global outcomes” (KDIGO) controversies conference;Schiffmann;Kidney Int.,2017

4. Anderson-fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males;MacDermot;J Med Genet.,2001

5. Anderson-fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females;MacDermot;J Med Genet.,2001

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fabry nephropathy: a treatable cause of chronic kidney disease;Rare Disease and Orphan Drugs Journal;2024-07-11

2. Longitudinal biomarker evaluation in Fabry disease patients receiving lentivirus-mediated gene therapy;Rare Disease and Orphan Drugs Journal;2024-06-27